We are an international orphan drug development and commercialization company headquartered in Paris.

Founded in 2011, we develop and deliver innovative therapies for people living with rare and debilitating diseases. Our trientine tetrahydrochloride product has been approved for the treatment of Wilson disease and is available in 30+ countries, branded as Cuprior® / Cuvrior®.